Announcements Trials
Browse Landscape

Phase

Phase NA 1Phase 2 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Lymphoma 7Lymphoma, Large B-Cell, Diffuse 6Precursor Cell Lymphoblastic Leukemia-Lymphoma 4Lymphoma, Non-Hodgkin 3Lymphoma, Follicular 3Leukemia 3Lymphoma, Large-Cell, Anaplastic 2Sezary Syndrome 1Respiratory Tract Diseases 1Rare Diseases 1Prostatic Neoplasms 1Nausea 1Mycosis Fungoides 1Lymphoma, T-Cell, Cutaneous 1Lymphoma, T-Cell 1Lymphoma, Mantle-Cell 1Lymphoma, Extranodal NK-T-Cell 1Lymphoma, B-Cell, Marginal Zone 1Leukemia, Biphenotypic, Acute 1Immunoblastic Lymphadenopathy 1Hormone Refractory Prostate Cancer 1Hemangioma 1Esophageal Stenosis Acquired 1Dendritic Cell Sarcoma, Interdigitating 1COVID-19 1Ataxia Telangiectasia 1Ataxia 1

Interventions

Prednisone 1PE regimen 1Injections 1Etoposide 1Docetaxel 1Cisplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase NA × Hormone Refractory Prostate Cancer × Prednisone × Clear all
NCT02208583 2014-08-05

Molecular Phenotype Changes and Personalized Treatment for CRPC

Tianjin Medical University Cancer Institute and Hospital

Phase NA Unknown
150 enrolled
Genitourinary

Hormone Refractory Prostate Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡